Project NextGen: Next Generation Medical Countermeasures

BARDA, in collaboration with the National Institute of Allergy and Infectious Diseases, is supporting the development of next generation medical countermeasures, including vaccines and therapeutics, to protect Americans from public health security threats such as coronaviruses. While existing vaccines against COVID-19 are still very effective at preventing serious illness and death, they are less capable of reducing infection and transmission over time. Similarly, previously authorized monoclonal antibody therapeutics critical to treating individuals and protecting some of our most vulnerable populations are not effective against currently circulating strains in the U.S.

New variants, waning immunity, and resistance to therapeutics will continue to challenge our healthcare systems in the coming years, leading to a critical need to develop novel vaccines and therapeutics.

Through Project NextGen, the U.S. government will leverage public-private partnerships to develop new vaccines and therapeutics to better address current SARS-CoV-2 viral strains and prepare for future ones.

Robert Johnson, Director of Medical Countermeasures, provides a brief introduction to the Project NextGen Initiative.

Read the BARDA NextGen Fact Sheet: Download

BARDA’s Project NextGen Focus Areas

Better Protection and Longer Lasting Vaccines: Vaccines that provide broader protection against variants of concern and a longer duration of protection.
Vaccines that are Easier to Administer and Reduce Spread of the Virus: Including mucosal vaccines such as those delivered intranasally, which could have the potential to dramatically reduce infection and transmission, in addition to preventing serious illness and death.
Pan-Coronavirus Protection: Pan-coronavirus vaccines which protects against several different coronaviruses.

Modernized, More Resilient Treatment: New and more durable monoclonal antibodies that are resilient against new variants as they arise.
Innovative Solutions for Faster, Lower Cost, Rapidly Deployable Technologies: Advancing new technologies that will improve access and enable faster, lower cost, rapid, and flexible production of vaccines and therapeutics.

PROGRAM AREAS OF ADVANCED RESEARCH AND DEVELOPMENT

STRENGTHEN

COVID-19 VACCINES

View Details

TREAT

COVID-19 THERAPEUTICS

View Details

ENABLE

ADVANCED TECHNOLOGY

View Details

BARDA'S PROJECT NEXTGEN PORTFOLIO

This page is updated regularly, but may not include all awards

Program Area Filters

All
Vaccines
Therapeutics
Enablers
Partnerships

Opportunities

BARDA is seeking information and submissions regarding COVID-19 vaccines and therapeutics.
We will continue to update our Broad Agency Announcement and EZ-BAA with Project NextGen partnership opportunities and encourage you to check out our Project NextGen website for more information. Review our current partnership opportunities:

EVENTS

On July 20, BARDA hosted the Project NextGen: Enablers for Innovative COVID-19 Vaccine Manufacturing virtual workshop to engage with the vaccine development and manufacturing communities. The goal of the workshop was to gather feedback and identify opportunities that address vaccine manufacturing challenges and gaps to meet the goals of Project NextGen. The event featured speakers from NIIMBL, BIO, and FDA CBER and a panel discussion that also included BARDA Subject Matter Experts. Topics included upstream and downstream processing, formulation and analytical support. Over 400 individuals from across the industry attended the workshop.

Watch the entire workshop

SUBMIT A TECHWATCH MEETING REQUEST

Submit a TechWatch meeting request for next generation medical countermeasures to address COVID-19.

Prior to submitting to the Broad Agency Announcement (BAA), we encourage interested parties to request a TechWatch meeting for the opportunity to receive feedback from BARDA staff. Submission of a TechWatch Meeting Request does not guarantee a meeting or funding. Additional dates will be added pending future Area of Interest (AOI) openings.

LEARN ABOUT TECHWATCH

FUNDING OPPORTUNITIES

The Rapid Response Partnership Vehicle (RRPV) supports BARDA to accelerate the advanced development of MedicalCountermeasure (MCM) products and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.

EXPLORE RRPV OPPORTUNITIES

The Patch Forward Prize, part of Project NextGen, is a $50 million competition to advance microneedle patch-based RNA vaccines for COVID-19, seasonal influenza, and pandemic influenza. BARDA calls on vaccine developers and patch makers to partner and accelerate new vaccine technologies.

EXPLORE PATCH FORWARD PRIZE